Dr Gertz on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Morie A. Gertz, MD, discusses the rationale for the phase 3 AFFIRM-AL trial in patients with amyloid light chain amyloidosis and elaborates on the challenges that may arise when enrolling patients to this trial.

Related Keywords

Moriea Gertz , ,Mayo Clinic Comprehensive Cancer Center ,General Internal Medicine ,Mayo Stage ,Physical Component Summary ,D ,Affirm Al Trial ,Patients With Amyloid Light Chain Amyloidosis ,Nct04973137 ,